WeSearch

STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more

Ed Silverman· ·4 min read · 0 reactions · 0 comments · 8 views
STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more

Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug retatrutide

Original article
STAT · Ed Silverman
Read full at STAT →
Opening excerpt (first ~120 words) tap to expand

STAT PlusNewsletterPharmalot Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more Combination of pancreatic cancer drugs from Tango and Revolution leads to a high response rate Manage alerts for this article Email this article Share this article Alex Hogan/STAT By Ed SilvermanJune 8, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Good morning, everyone, and welcome to another working week.

…

Excerpt limited to ~120 words for fair-use compliance. The full article is at STAT.

Anonymous · no account needed
Share 𝕏 Facebook Reddit LinkedIn Threads WhatsApp Bluesky Mastodon Email

Discussion

0 comments

More from STAT

STAT+: Novo underwhelmed by drug it once fought Pfizer for
STAT·9
Opinion: How the Amish think about vaccines, health care costs, and much more
STAT·17
Opinion: I led the U.S. CDC response to the 2014 Ebola epidemic. The new outbreak needs massive, immediate, meticulous action
STAT·16
STAT+: Newer GLP-1s, pushback on research cuts, and a protest
STAT·19
STAT+: Up and down the ladder: The latest comings and goings
STAT·15
STAT+: Will Makary’s FDA voucher program survive?
STAT·18